The primary objective of this study is to validate a pre-defined IL-6 concentration cutoff that predicts 28-day mortality in patients who are admitted or are intended to be admitted to the ICU diagnosed with sepsis or septic shock.
Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.
Bluejay Diagnostics, Inc. (BJDX) is the sponsoring company for this trial. BiotechSign currently grades this company F (15/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.